Merck & Co.(MRK) said Monday its investigational sacituzumab tirumotecan therapy met primary endpoints of overall survival and progression-free survival in a phase 3 trial for advanced or recurrent endometrial cancer.
The medication improved survival metrics and achieved its secondary objective response rate goal compared to standard chemotherapy in patients previously treated with other therapies, the company said.
The safety profile of the drug remained consistent with prior studies, and the clinical data will be shared with global regulatory authorities, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments